Clerio Vision, Inc.

Clerio Vision, Inc. is a development-stage medical device company based in West Henrietta, New York, founded in 2014.

The company is focused on creating non-invasive vision correction solutions using its proprietary Laser-Induced Refractive Index Correction (LIRIC) technology, which is licensed from the University of Rochester. This innovative approach aims to address unmet needs in vision care for millions of people worldwide. Clerio Vision is currently in the clinical development phase, working on a range of next-generation products targeting the contact lens, intraocular lens (IOL), and laser vision correction markets. Their technology allows for non-invasive modifications to the refractive index of ocular tissues, potentially improving safety and performance compared to existing treatments. The company is led by CEO Mikael Totterman and has a team of experienced professionals in the ophthalmic industry. With significant funding and a strong patent portfolio, Clerio Vision is poised to make a meaningful impact in the field of vision correction.